Friday 19 March

Wednesday 17 March

Thursday 18 March

Session 6:

Diagnostic Technologies & Interpretation Approaches

Invited lecture: Future applications of full length viral genome sequencing

P. Kellam

Pres.

Pyrosequencing of HIV-1 reverse transcriptase to reveal minority populations of resistant virus before start of a NNRTI-based regimen.

L. Vandekerckhove

Abs.

Pres.

The influence of PCR amplification variation on the ability of population-based PCR to detect non-R5 HIV

R. Harrigan

Abs.

Pres.

Detection of predicted CXCR4-using HIV-1 variants in longitudinally obtained paired plasma and PBMC samples using 454-sequencing

A. van 't Wout

Abs.

N.A.

Use of a genotypic assay for prediction of HIV-1 co-receptor tropism and guiding the use of CCR5 antagonists in clinical practice.

M. Macartney

Abs.

Pres.

Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study)

M. Zazzi

Abs.

Pres.

Bayesian network analysis of resistance pathways in HIV-2 reverse transcriptase

J. Cavaco Silva

Abs.

Pres.

Session 7:

Clinical Case Presentations

Treating Mexican flu in an immuno-compromised patient:  a great challenge!

C. Boucher

Pres.

Tropism testing on proviral DNA to guide the use of Maraviroc in clinical practice

N. Mackie

Pres.

The challenge of treating HIV+ patients with chronic hepatitis C due to genotype 1 and high viral load

V. Soriano

Pres.

Session 8:

Clinical Implications of HIV drug resistance

Invited lecture: Treatment of resistant TB in HIV infected patients

A. Gori

Pres.

HIV drug resistance patterns of maternal HAART cohorts to prevent HIV

postnatal mother-to-child transmission in Rwanda

J-C. Karasi

Abs.

Pres.

Differences in susceptibility to Darunavir and Etravirine reported by two genotypic interpretation systems.

F. Garcia

Abs.

Pres.

Do NRTIs improve effectiveness of salvage regimens containing three new class/generation antiretrovirals in multidrug resistant HIV infected patients?

A. Imaz

Abs.

Pres.

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir containing regimen (ANRS 139 trio trial).

B. Roquebert

Abs.

Pres.

A case of super infection with multi-resistant HIV-1 and rapid progression to AIDS despite immediate intervention with MegaHAART including new classes

A. Capetti

Abs.

Pres.

Session 9:

Clinical Implications of HIV drug resistance

High prevalence of epidemiological networks involving primary resistance in chronically infected HIV-1 naive individuals

A. Lai

Abs.

Pres.

Detection of drug resistance mutations (DRM) at low viral load in a European multicohort study (SEHERE)

M. Prosperi

Abs.

Pres.

Temporal changes in HIV drug resistant prevalence across the World. Review

D. Frentz

Abs.

Pres.

COMET: A Novel approach to HIV-1 subtype prediction.

D. Struck

Abs.

N.A.

Sudden viral load increase as an indicator of HIV-1 superinfection in HAART-naive HIV-infected patients

T. Doyle

Abs.

Pres.